Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study | Zendy

Gregory Huhn | Zendy; Gordon Crofoot | Zendy; Moti Ramgopal | Zendy; Joseph Gathe | Zendy; Robert Bolan | Zendy; Donghan Luo | Zendy; Richard Bruce Simonson | Zendy; Richard E. Nettles | Zendy; Carmela Benson | Zendy; Keith Dunn | Zendy

Open Access

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study

Author(s) -

Gregory Huhn,

Gordon Crofoot,

Moti Ramgopal,

Joseph Gathe,

Robert Bolan,

Donghan Luo,

Richard Bruce Simonson,

Richard E. Nettles,

Carmela Benson,

Keith Dunn

Publication year - 2019

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciz1213

Subject(s) - tenofovir alafenamide , emtricitabine , medicine , darunavir , cobicistat , adverse effect , regimen , clinical endpoint , viral load , human immunodeficiency virus (hiv) , virology , clinical trial , antiretroviral therapy

Most guidelines recommend rapid treatment initiation for patients with newly diagnosed human immunodeficiency virus type 1 (HIV-1) infection, but prospective US data are limited. The DIAMOND (NCT03227861) study using darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is a phase 3 prospective study evaluating efficacy/safety of a single-tablet regimen in a rapid-initiation model of care.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research